Skip to main content

Table 1 General features of patients with dermatomyositis with versus without anti-Jo-1 autoantibodies

From: The relevance of anti-Jo-1 autoantibodies in patients with definite dermatomyositis

  Anti-Jo-1 (+)
(n = 10)
Anti-Jo-1 (−)
(n = 108)
P value
Age at diagnosis (years) 46.5 ± 16.4 43.9 ± 15.6 0.638
Sex: female 5 (50.0) 77 (71.3) 0.171
Ethnicity: white 9 (90.0) 86 (79.6) 0.684
Disease duration (years) 5.0 [1.8–8.0] 7.0 [4.0–12.0] 0.093
Duration of follow-up (months) 36.6 [18.8–95.6] 56.0 [27.5–85.5] 0.804
Constitutional symptoms (baseline) 9 (90.0) 77 (71.3) 0.283
Cumulative manifestations
 Cutaneous involvement
  Gottron papules 10 (100.0) 108 (100.0) > 0.999
  Gottron sign 10 (100.0) 108 (100.0) > 0.999
  Heliotrope eruption 10 (100.0) 108 (100.0) > 0.999
  Facial erythema 5 (50.0) 88 (81.5) 0.034
  Raynaud phenomenon 8 (80.0) 62 (57.4) 0.312
  “V-neck” sign 3 (30.0) 71 (65.7) 0.044
  “Shawl” sign 4 (40.0) 54 (50.0) 0.036
  Vasculitis 0 37 (34.3)
  Digital ulcers 0 31 (28.7)
  Periungual erythema 7 (70.0) 84 (77.8) 0.694
  “Mechanic’s hands” 7 (70.0) 13 (12.0) < 0.001
  Calcinosis cutis 0 7 (65.0)
 Joint involvement 8 (80.0) 34 (31.5) 0.004
 Lung involvement 10 (100.0) 33 (30.6) < 0.001
  Dyspnea 8 (80.0) 30 (28.7) 0.002
  Incipient interstitial lung disease 10 (100.0) 28 (25.9) < 0.001
  Pulmonary fibrosis 1 (10.0) 4 (3.7) 0.363
  Ground-glass opacities 6 (60.0) 7 (6.5) < 0.001
Laboratory findings
 Antinuclear antibodies 9 (90.0) 81 (75.0) > 0.999
 Anti-Mi-2 0 12 (11.1)
 Anti-Ro-52 2 (20.0) 22 (20.4) > 0.999
 Maximum creatine kinase levels (U/L) 4522 [2173–13,500] 2208 [253–8394] 0.118
 Maximum aldolase levels (U/L) 50 [20.6–74.8] 28.1 [9.0–90.5] 0.617
  1. Data are shown as means ± standard deviations, medians [interquartile ranges], or number of patients (%)